Global Lung Cancer Therapeutics Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2015 Future Market Insights www.futuremarketinsights.com [email protected] Report Description Report Description Lung cancer is a malignant tumor characterized by uncontrolled growth of cell tissues in the lung. Itis the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. American Lung Association has estimated that around 224,210new cases were diagnosed with lung cancer in the American region that accounts for approximately 13% of all the cancer cases diagnosed. Thus, with the rise in incidence rate of lung cancer, the demand for therapeutics is also expected to grow during the study period. Based on the cancer cell types, lung cancer is broadly segmented as small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC segment accounts for approximately 80 to 90% of all lung cancers. Based on the cell shape and size, NSCLC is further divided to three subtypes, they are adenocarcinoma, large-cell carcinoma and squamous cell carcinoma. These NSCLC’s are primarily treated with the surgeries, at the same time chemotherapy is increasingly used for both pre-operative and post-operative treatment of the patients. The treatment options available for the NSCLC include surgery, radiation therapy and chemotherapy. As per the American Cancer Society, it was estimated that in the United States approximately 195,000 peopleare suffering from NSCLC every year and the number of deaths from NSCLC are approximately 135,000. The top five global brands that are commercially available in the market are Avastin, Tarceva, Alimta, Gemzar and Taxotere. Thus, all the above mentioned factors collectively drive the growth of the global lung cancer therapeutics market. Browse Full Report@ http://www.futuremarketinsights.com/reports/lung-cancertherapeutics-market Report Description Report Description The global lung cancer therapeutics market can be segmented as follows: By Drugs • Hycamtin • Taxotere • Gemzar • Alimta • Iressa • Avastin • Tarceva Pipeline Drugs • Xalkori • Afatinib • Dacomitinib • ARQ 197 • Talactoferrin Report Description Report Description Increasing incidences of lung cancer due to rising smoking population is one of the major factors driving the growth of lung cancer therapeutics market. The risk of lung cancer is tenfold higher in smokers as compared to non-smokers. In addition, launch of premium priced drugs, new innovative radiation therapies coupled with rising incidences of NSCLC are the major driving factors for the growth of lung cancer therapeutics market. However, genericization of the major drugs might restrict the growth of this market. Request Report TOC@ http://www.futuremarketinsights.com/toc/rep-gb-422 Geographically, North America and Europe dominates the global lung cancer therapeutics market. According to Lung Disease Research Funding, approximately 75,000 people in the U.S. die because of lung injury every year. The United States is the largest market for NSCLC owing to the high incidence rate, rise in aging population. In addition, with advent of new treatment therapies such as targeted drug therapy, stereotacticsare aiding patient population. Europe accounts to be the largest market after North America.While, AsiaPacific countries such as India and China, South East Asia are the emerging regions for the global lung cancer therapeutics market due to high prevalence of this diseasecoupled with increasing healthcare awareness. Players are adopting various strategies to expand their product portfolio and increase its geographical presence. New product development, agreements and collaborations and acquisitions are some of the important strategies adopted by the players in the global lung cancer therapeutics market. The prominent leading players of this market include AstrazenecaPlc, Eli Lilly and Company, GlaxoSmitKline, Hoffman-La Roche, About Us Report Description Future Market Insights Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Research Capabilities Customized Research Syndicated Research Investment Research Social Media Research Sector Coverage Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas Thank You! To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: [email protected] For other queries contact: Mr. Sudip Saha Future Market Insights: 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 | D: +1-845-579-5705
Lung cancer is a malignant tumor characterized by uncontrolled growth of cell tissues in the lung. Itis the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. American Lung Association has estimated that around 224,210new cases were diagnosed with lung cancer in the American region that accounts for approximately 13% of all the cancer cases diagnosed. Thus, with the rise in incidence rate of lung cancer, the demand for therapeutics is also expected to grow during the study period.
© Copyright 2024 Paperzz
